| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Department of Pathology,*
Albert Einstein
College of Medicine, Bronx, New York; and the Department of
Pathology,
University of Washington,
Seattle, Washington
The Cdc25 phosphatases play key roles in cell-cycle progression by activating cyclin-dependent kinases. The latter are absent from neurons that are terminally differentiated in adult brain. However, accumulation of mitotic phosphoepitopes, and re-expression and activation of the M phase regulator, Cdc2/cyclin B, have been described in neurons undergoing degeneration in Alzheimer’s disease (AD). To explain this atypical mitotic activation in neurons we investigated the Cdc2-activating Cdc25A phosphatase in human brain. The structural hallmarks of AD neurodegeneration, neurofibrillary tangles and neuritic plaques, were prominently immunolabeled with Cdc25A antibodies. In addition numerous neurons without visible structural alterations were also intensely stained, whereas control brain was very weakly positive. After immunoprecipitation from control and AD tissue, we found that the tyrosine dephosphorylating activity of Cdc25A against exogenous Cdc2 substrate was elevated in AD. Accordingly, Cdc25A from AD tissue displayed increased immunoreactivity with the mitotic phosphoepitope-specific antibody, MPM-2, and co-localized with MPM-2 immunoreactivity in AD neurons. These data suggest that Cdc25A participates in mitotic activation during neurodegeneration. The involvement of Cdc25A in cellular transformation, modulation of the DNA damage checkpoint, and linkage of mitogenic signaling to cell cycle machinery, also implicates one of these cell-cycle pathways in AD pathogenesis.
This article has been cited by other articles:
 |
|
 |
|
  B. Mosch, M. Morawski, A. Mittag, D. Lenz, A. Tarnok, and T. Arendt Aneuploidy and DNA Replication in the Normal Human Brain and Alzheimer's Disease J. Neurosci., June 27, 2007; 27(26): 6859 - 6867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhang, D. Qu, E. J. Morris, M. J. O'Hare, S. M. Callaghan, R. S. Slack, H. M. Geller, and D. S. Park The Chk1/Cdc25A Pathway as Activators of the Cell Cycle in Neuronal Death Induced by Camptothecin. J. Neurosci., August 23, 2006; 26(34): 8819 - 8828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Delobel, I. Lavenir, B. Ghetti, M. Holzer, and M. Goedert Cell-Cycle Markers in a Transgenic Mouse Model of Human Tauopathy: Increased Levels of Cyclin-Dependent Kinase Inhibitors p21Cip1 and p27Kip1 Am. J. Pathol., March 1, 2006; 168(3): 878 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D'Ambrosio, S. Arena, G. Fulcoli, M. H. Scheinfeld, D. Zhou, L. D'Adamio, and A. Scaloni Hyperphosphorylation of JNK-interacting Protein 1, a Protein Associated with Alzheimer Disease Mol. Cell. Proteomics, January 1, 2006; 5(1): 97 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. F. McCain, L. Wu, P. Nickel, M. U. Kassack, A. Kreimeyer, A. Gagliardi, D. C. Collins, and Z.-Y. Zhang Suramin Derivatives as Inhibitors and Activators of Protein-tyrosine Phosphatases J. Biol. Chem., April 9, 2004; 279(15): 14713 - 14725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Shulman and M. B. Feany Genetic Modifiers of Tauopathy in Drosophila Genetics, November 1, 2003; 165(3): 1233 - 1242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Qu, J. N. Weiss, and W. R. MacLellan Regulation of the mammalian cell cycle: a model of the G1-to-S transition Am J Physiol Cell Physiol, February 1, 2003; 284(2): C349 - C364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Lazo, K. Nemoto, K. E. Pestell, K. Cooley, E. C. Southwick, D. A. Mitchell, W. Furey, R. Gussio, D. W. Zaharevitz, B. Joo, et al. Identification of a Potent and Selective Pharmacophore for Cdc25 Dual Specificity Phosphatase Inhibitors. Mol. Pharmacol., April 1, 2002; 61(4): 720 - 728. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
